1. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapiesin lymphoid malignancies. Nat Rev Clin Oncol. 2016;13(1):25-40.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014 [publishedcorrection appears in CA Cancer J Clin. 2014;64(5):364]. CA Cancer JClin. 2014;64(1):9-29. doi:10.3322/caac.21208
3. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication ofB-lineage cells and regression of lymphoma in a patient treated withautologous T cells genetically engineered to recognize CD19. Blood.2010;116(20):4099-4102. doi:10.1182/blood-2010-04-281931
4. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion andremissions of malignancy along with cytokine-associated toxicity ina clinical trial of anti-CD19 chimeric-antigen-receptor-transduced Tcells. Blood. 2012;119(12):2709-2720. doi:10.1182/blood-2011-10-384388
5. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1receptors inhibit T-cell activation by distinct mechanisms. Mol CellBiol. 2005;25(21):9543-9553. doi:10.1128/MCB.25.21.9543-9553.2005
6. Pardoll DM. The blockade of immune checkpoints in cancerimmunotherapy. Nat Rev Cancer. 2012;12(4):252-264.doi:10.1038/nrc3239
7. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1promotes T-cell apoptosis: a potential mechanism of immune evasion[published correction appears in Nat Med 2002;8(9):1039]. Nat Med.2002;8(8):793-800. doi:10.1038/nm730
8. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloiddendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562-567. doi:10.1038/nm863
9. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinibin relapsed or refractory mantle-cell lymphoma. N Engl J Med.2013;369(6):507-516. doi:10.1056/NEJMoa1306220
10. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat RevDrug Discov. 2012;11(1):19-20. doi:10.1038/nrd3629
11. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase IIstudy of brentuximab vedotin for patients with relapsed or refractoryHodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189. doi:10.1200/JCO.2011.38.0410
12. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractoryCD30+ lymphomas: a bridge to allogeneic transplantation inapproximately one quarter of patients treated on a Named PatientProgramme at a single UK center. Haematologica. 2013;98(4):611-614.doi:10.3324/haematol.2012.069393
13. Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) inpatients with transplant-naive relapsed/refractory Hodgkin lymphoma.Leuk Lymphoma. 2013;54(10):2144-2148. doi:10.3109/10428194.2013.775434
14. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab:a historical perspective. Pharmacol Ther. 2012;136(3):334-342.doi:10.1016/j.pharmthera.2012.07.013
15. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumabin previously treated chronic lymphoid leukemia. N Engl J Med.2014;371(3):213-223. doi:10.1056/NEJMoa1400376
16. Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, CugnoM. Current and emerging treatment options for patients with relapsedmyeloma. Clin Med Insights Oncol. 2013;7:209-219. doi:10.4137/CMO.S8014
17. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitorof phosphatidylinositol 3-kinase-δ, as therapy for previously treatedindolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406-3413.doi:10.1182/blood-2013-11-538546
18. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab inrelapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997-1007. doi: 10.1056/NEJMoa1315226
19. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle celllymphoma in the United States between 1992 and 2004. Cancer.2008;113(4):791-798. doi:10.1002/cncr.23608
20. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide inpatients with mantle-cell lymphoma who relapsed or progressed afteror were refractory to bortezomib: phase II MCL-001 (EMERGE) study.J Clin Oncol. 2013;31(29):3688-3695. doi:10.1200/JCO.2013.49.2835
21. Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, CugnoM. Current and emerging treatment options for patients with relapsedmyeloma. Clin Med Insights Oncol. 2013;7:209-219. doi:10.4137/CMO.S8014
22. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cellsand their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-821. doi:10.1038/s41423-020-0488-6